{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T19:06:11Z","timestamp":1772478371262,"version":"3.50.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02998","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T03:31:41Z","timestamp":1545103901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Targeting Costimulatory Pathways in Systemic Sclerosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Gon\u00e7alo","family":"Boleto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.it.2005.09.004","article-title":"Scleroderma: from cell and molecular mechanisms to disease models","volume":"26","author":"Abraham","year":"2005","journal-title":"Trends Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatol Oxf Engl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","article-title":"Transforming growth factor beta as a therapeutic target in systemic sclerosis","volume":"5","author":"Varga","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/1074-7613(95)90000-4","article-title":"New perspectives of CD28-B7-mediated T cell costimulation","volume":"2","author":"Bluestone","year":"1995","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar2414","article-title":"T-cell co-stimulatory pathways in autoimmunity","volume":"10","author":"Goronzy","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.smim.2011.04.002","article-title":"Costimulatory pathways in transplantation","volume":"23","author":"Pilat","year":"2011","journal-title":"Semin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1600-065X.2009.00773.x","article-title":"Molecular mechanisms of T cell receptor and costimulatory molecule ligation\/blockade in autoimmune disease therapy","volume":"229","author":"Podojil","year":"2009","journal-title":"Immunol Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2249.2004.02427.x","article-title":"Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sj\u00f6gren's syndrome and systemic sclerosis","volume":"136","author":"Hebbar","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ard.2009.116434","article-title":"Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis","volume":"69","author":"Gourh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/rheumatology\/keh303","article-title":"Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis","volume":"43","author":"Sato","year":"2004","journal-title":"Rheumatol Oxf Engl"},{"key":"B15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1517\/14728222.6.3.275","article-title":"Targeting T cell costimulation in autoimmune disease","volume":"6","author":"Stuart","year":"2002","journal-title":"Expert Opin Ther Targets"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.imlet.2018.03.011","article-title":"Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations","volume":"198","author":"Dantas","year":"2018","journal-title":"Immunol Lett"},{"key":"B17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/cyto.a.20383","article-title":"ICOS and B7 costimulatory molecule expression identifies activated cellular subsets in rheumatoid arthritis","volume":"71","author":"Ruth","year":"2007","journal-title":"Cytom Part J Int Soc Anal Cytol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1002\/art.20519","article-title":"Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus","volume":"50","author":"Hutloff","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B19","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood.V96.8.2808","article-title":"Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00403-012-1292-7","article-title":"Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis","volume":"305","author":"Yanaba","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/rheumatology\/kes258","article-title":"Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis","volume":"52","author":"Hasegawa","year":"2013","journal-title":"Rheumatol Oxf Engl."},{"key":"B22","first-page":"2108","article-title":"Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells","volume":"166","author":"Nohara","year":"2001","journal-title":"J Immunol Baltim Md 1950"},{"key":"B23","first-page":"49","article-title":"Outside inside signalling in CD40-mediated B cell activation","volume":"21","author":"D'Orlando","year":"2007","journal-title":"J Biol Regul Homeost Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3899\/jrheum.080120","article-title":"Increased serum soluble OX40 in patients with systemic sclerosis","volume":"35","author":"Komura","year":"2008","journal-title":"J Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/ard.2010.141838","article-title":"A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort","volume":"70","author":"Bossini-Castillo","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"E3901","DOI":"10.1073\/pnas.1523512113","article-title":"OX40L blockade protects against inflammation-driven fibrosis","volume":"113","author":"Elhai","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s10875-012-9735-7","article-title":"Matrix metalloproteinases: a review of their structure and role in systemic sclerosis","volume":"32","author":"Peng","year":"2012","journal-title":"J Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.celrep.2014.10.067","article-title":"Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses","volume":"9","author":"Godefroy","year":"2014","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccr.2011.01.037","article-title":"Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway","volume":"19","author":"Godefroy","year":"2011","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/jaut.2000.0387","article-title":"Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients","volume":"15","author":"Valentini","year":"2000","journal-title":"J Autoimmun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/eji.200324088","article-title":"Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts","volume":"33","author":"Fukasawa","year":"2003","journal-title":"Eur J Immunol"},{"key":"B32","first-page":"353","article-title":"Increased serum soluble CD40 levels in patients with systemic sclerosis","volume":"34","author":"Komura","year":"2007","journal-title":"J Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00296-007-0393-7","article-title":"High expression of CD40 on skin fibroblasts from patients with systemic sclerosis","volume":"28","author":"Jun","year":"2007","journal-title":"Rheumatol Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.34376","article-title":"DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility","volume":"64","author":"Lian","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.biocel.2015.05.023","article-title":"Epigenetic mechanisms: an emerging role in pathogenesis and its therapeutic potential in systemic sclerosis","volume":"67","author":"Luo","year":"2015","journal-title":"Int J Biochem Cell Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/ard.2003.020040","article-title":"Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers","volume":"64","author":"Allanore","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.mvr.2016.07.002","article-title":"Capillaroscopic findings and vascular biomarkers in systemic sclerosis: association of low CD40L levels with late scleroderma pattern","volume":"108","author":"Yal\u00e7inkaya","year":"2016","journal-title":"Microvasc Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3899\/jrheum.160833","article-title":"Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment","volume":"44","author":"Haddon","year":"2017","journal-title":"J Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/annrheumdis-2012-201759","article-title":"Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis","volume":"72","author":"Avouac","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/art.30204","article-title":"Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis","volume":"63","author":"Dieud\u00e9","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B41","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1186\/ar3809","article-title":"A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis","volume":"14","author":"Bossini-Castillo","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4049\/jimmunol.1403046","article-title":"Increased CD226 expression on CD8+ t cells is associated with upregulated cytokine production and endothelial cell injury in patients with systemic sclerosis","volume":"195","author":"Ayano","year":"2015","journal-title":"J Immunol Baltim Md 1950"},{"key":"B43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J Cutan Pathol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","article-title":"The soluble CTLA-4 receptor and its role in autoimmune diseases: an update","volume":"1","author":"Saverino","year":"2010","journal-title":"Auto Immun Highlights"},{"key":"B48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3109\/08820139.2013.789910","article-title":"The CTLA-4 and MCP-1 polymorphisms and susceptibility to systemic sclerosis: a meta-analysis","volume":"42","author":"Song","year":"2013","journal-title":"Immunol Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11926-015-0554-8","article-title":"Macrophage involvement in systemic sclerosis: do we need more evidence?","volume":"18","author":"Stifano","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1151594","DOI":"10.1080\/2162402X.2016.1151594","article-title":"CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma","volume":"5","author":"Yu","year":"2016","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/1346-8138.13339","article-title":"Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: association with extent of skin sclerosis","volume":"43","author":"Yanaba","year":"2016","journal-title":"J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/art.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5301\/jsrd.5000207","article-title":"Emerging strategies for treatment of systemic sclerosis","volume":"1","author":"Khanna","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"B55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2172-12-67","article-title":"Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension","volume":"12","author":"Rabieyousefi","year":"2011","journal-title":"BMC Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","article-title":"Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis","volume":"75","author":"Ponsoye","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B58","unstructured":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3109\/03009742.2013.812238","article-title":"Abatacept induces clinical improvement in patients with severe systemic sclerosis","volume":"43","author":"de","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.clinthera.2010.10.011","article-title":"Safety profile of abatacept in rheumatoid arthritis: a review","volume":"32","author":"Khraishi","year":"2010","journal-title":"Clin Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T11:10:12Z","timestamp":1573557012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2018.02998"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02998","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"article-number":"2998"}}